Log in to save to my catalogue

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1693216023

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

The addition of nivolumab (anti–PD-1) to ipilimumab (anti–CTLA-4) did not further improve response rate or progression-free survival among patients with PD-L1–positive tumors. The combination was much more effective in patients with PD-L1–negative tumors.
Considerable progress in the treatment of metastatic melanoma has been made in the past 5 y...

Alternative Titles

Full title

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_1693216023

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1693216023

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1504030

How to access this item